Rhumbline Advisers Reduces Position in Momenta Pharmaceuticals, Inc. (MNTA)

Share on StockTwits

Rhumbline Advisers reduced its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 2.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 181,276 shares of the biotechnology company’s stock after selling 4,681 shares during the quarter. Rhumbline Advisers’ holdings in Momenta Pharmaceuticals were worth $4,768,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at approximately $108,000. Sawtooth Solutions LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at approximately $227,000. Pillar Pacific Capital Management LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at approximately $231,000. Essex Investment Management Co. LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at approximately $330,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at approximately $284,000. 95.71% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently issued reports on MNTA. BidaskClub lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 18th. ValuEngine raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research reissued a “hold” rating on shares of Momenta Pharmaceuticals in a research report on Wednesday, November 14th. Stifel Nicolaus reissued a “buy” rating and set a $40.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 10th. Finally, Piper Jaffray Companies began coverage on Momenta Pharmaceuticals in a research report on Monday, November 5th. They set an “overweight” rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $27.00.

MNTA stock opened at $14.25 on Friday. Momenta Pharmaceuticals, Inc. has a 12-month low of $10.10 and a 12-month high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.18. The firm had revenue of $14.88 million during the quarter, compared to the consensus estimate of $16.99 million. Momenta Pharmaceuticals had a negative return on equity of 44.72% and a negative net margin of 158.21%. The firm’s revenue was down 38.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.44) EPS. On average, sell-side analysts predict that Momenta Pharmaceuticals, Inc. will post -2.69 earnings per share for the current year.

In related news, CEO Craig A. Wheeler sold 4,374 shares of the company’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $13.50, for a total transaction of $59,049.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 8,136 shares of company stock valued at $106,026. 4.80% of the stock is owned by company insiders.

WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/12/08/rhumbline-advisers-reduces-position-in-momenta-pharmaceuticals-inc-mnta/3064503.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

See Also: Diversification

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.